United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Primary listing
Employees
1,305
Headquarters
Website
UTHR Metrics
BasicAdvanced
$18B
15.75
$25.63
0.53
-
Price and volume
Market cap
$18B
Beta
0.53
52-week high
$436.95
52-week low
$266.98
Average daily volume
805K
Financial strength
Current ratio
7.26
Quick ratio
6.504
Interest coverage (TTM)
48.32%
Profitability
EBITDA (TTM)
1,597.1
Gross margin (TTM)
88.98%
Net profit margin (TTM)
40.36%
Operating margin (TTM)
49.30%
Effective tax rate (TTM)
23.18%
Revenue per employee (TTM)
$2,360,000
Management effectiveness
Return on assets (TTM)
12.96%
Return on equity (TTM)
19.30%
Valuation
Price to earnings (TTM)
15.747
Price to revenue (TTM)
5.882
Price to book
2.54
Price to tangible book (TTM)
2.58
Price to free cash flow (TTM)
16.902
Free cash flow yield (TTM)
5.92%
Free cash flow per share (TTM)
23.88
Growth
Revenue change (TTM)
17.62%
Earnings per share change (TTM)
17.94%
3-year revenue growth (CAGR)
19.83%
10-year revenue growth (CAGR)
8.58%
3-year earnings per share growth (CAGR)
24.75%
10-year earnings per share growth (CAGR)
22.87%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Bulls say / Bears say
United Therapeutics shares soared over 42% in premarket trading after its late-stage TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis achieved its primary endpoint, improving forced vital capacity by 95.6 mL versus placebo over 52 weeks (Reuters).
In Q2 2025, United Therapeutics posted record revenue of $798.6 million—up 12% year-over-year—with Tyvaso DPI sales reaching $315.2 million (+22%). Its Board approved a $1 billion share repurchase program, showing robust financial performance and prudent capital allocation (Reuters via Tiger Brokers) (Reuters).
The FDA approved United Therapeutics’ IND for its UKidney program in January 2025, allowing a first-in-human trial of gene-edited pig kidneys. The initial cohort will enroll six patients and could expand to 50, representing a major milestone toward commercial xenotransplantation (SEC Filing)
Revenue for Q2 2025 of $798.6 million narrowly missed consensus forecasts of $804.98 million, highlighting sensitivity to market expectations despite record sales (Reuters).
United Therapeutics faces approaching generic competition as Liquidia’s Yutrepia could secure final approval once United’s Tyvaso DPI exclusivity expires in 2025, putting its core treprostinil franchise at risk (Reuters).
Xenotransplantation trials for pig kidney transplants present significant zoonotic infection risks, creating regulatory and safety challenges that could delay United Therapeutics’ organ manufacturing efforts (AFP via France24)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
Business Wire6 days ago
United Therapeutics: Is UTHR Stock Still A Buy At $400?
Forbes2 weeks ago
United Therapeutics shares jump on positive lung disease study results
Proactive Investors2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $18B as of September 18, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 15.75 as of September 18, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.